Legal & General Group
ABOS icon

Legal & General Group’s Acumen Pharmaceuticals ABOS Stock Holding History

Legal & General Group’s Portfolio ABOS Stock Details ABOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$12.3K Buy
+4,610
New +$11.4K ﹤0.01% 3276
2025
Q2 		– Sell
-3,635
Closed -$4K – 3417
2025
Q1 		$4K Hold
3,635
– – ﹤0.01% 3308
2024
Q4 		$6.25K Hold
3,635
– – ﹤0.01% 3323
2024
Q3 		$9.02K Hold
3,635
– – ﹤0.01% 3290
2024
Q2 		$8.8K Buy
+3,635
New +$11.6K ﹤0.01% 3323
2022
Q2 		– Sell
-2,762
Closed -$11K – 3512
2022
Q1 		$11K Buy
2,762
+1,874
+211% +$10.2K ﹤0.01% 3377
2021
Q4 		$6K Hold
888
– – ﹤0.01% 3530
2021
Q3 		$13K Buy
+888
New +$14.8K ﹤0.01% 3393

Other funds holding ABOS

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $614M AUM 19.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
KIA
Knollwood Investment Advisory Hunt Valley, Maryland $1.12B AUM 41.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

Legal & General Group's ABOS Position: Q2 2026 in Review

Legal & General Group opened a new position in Acumen Pharmaceuticals (ABOS) in Q2 2026: 4,610 shares worth $12.3K. The stake represents ﹤0.01% of the portfolio and ranks #3276 among its holdings. This is a return to the name: Legal & General Group previously reported a position in ABOS as recently as Q1 2025.

Legal & General Group first reported a position in ABOS in Q3 2021 and has held it in 8 quarters since. The position peaked at $13K in Q3 2021. 96 funds tracked by Wall St. Rank hold ABOS as of Q2 2026.

  • Legal & General Group held 4,610 shares of Acumen Pharmaceuticals worth $12.3K as of Q2 2026.
  • Acumen Pharmaceuticals was a new Legal & General Group position in Q2 2026.
  • Acumen Pharmaceuticals made up ﹤0.01% of Legal & General Group's portfolio in Q2 2026, its #3276 holding.
  • Legal & General Group first reported a position in Acumen Pharmaceuticals in Q3 2021 and has held it in 8 quarters since.
  • Legal & General Group's Acumen Pharmaceuticals position peaked at $13K in Q3 2021.
  • 96 funds tracked by Wall St. Rank held Acumen Pharmaceuticals as of Q2 2026.

Based on Legal & General Group's 13F filing for Q2 2026, filed 14 Aug 2026.